Magnetic resonance molecular imaging of thrombosis in an arachidonic acid mouse model using an activated platelet targeted probe

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 3, 2010, Pages 403-410

  Klink, Ahmed ^a,b   Lancelot, Eric ^c   Ballet, Sébastien ^c   Vucic, Esad ^a   Fabre, Jean Etienne ^d   Gonzalez, Walter ^c   Medina, Christelle ^c   Corot, Claire ^c   Mulder, Willem J M ^a   Mallat, Ziad ^b   Fayad, Zahi A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c Laboratoire Guerbet   (France)

^d UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Arterial thrombosis; Atherosclerosis; Magnetic resonance imaging; Platelets; Thrombosis

Indexed keywords

ARACHIDONIC ACID; EPTIFIBATIDE; GADOTERIC ACID; GLYCOPROTEIN; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; P 975; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CAROTID ARTERY; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE MODEL; DRUG PROTEIN BINDING; DRUG SPECIFICITY; FLUORESCENCE MICROSCOPY; IC 50; IMAGE ENHANCEMENT; IMAGE QUALITY; IN VITRO STUDY; MALE; MOLECULAR IMAGING; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; THROMBOCYTE ACTIVATION; THROMBOGENESIS; THROMBOSIS;

ANIMALS; ARACHIDONIC ACID; BLOOD PLATELETS; CAROTID ARTERY THROMBOSIS; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; FLUORESCENT DYES; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; ORGAN SPECIFICITY; ORGANOMETALLIC COMPOUNDS; PEPTIDES, CYCLIC; PLATELET ACTIVATION;

EID: 77649094952     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.198556     Document Type: Article

References (40)

1. Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature. 2008;451:953-957.
2. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque, part I: evolving concepts. J Am Coll Cardiol. 2005;46:937-954.
3. Gawaz M, Langer H, May AE. Platelets in inflammation and athero-genesis. J Clin Invest. 2005;115:3378-3384.
4. Massberg S, Brand K, Grüner S, Page S, Müller E, Müller I, Bergmeier W, Richter T, Lorenz M, Konrad I, Nieswandt B, Gawaz M. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med. 2002;196:887-896.
5. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myo-cardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myo-cardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50:e1-e157.
6. Briley-Saebo KC, Mulder WJ, Mani V, Hyafil F, Amirbekian V, Aguinaldo JG, Fisher EA, Fayad ZA. Magnetic resonance imaging of vulnerable atherosclerotic plaques: current imaging strategies and molecular imaging probes. J Magn Reson Imaging. 2007;26:460-479.
7. Choudhury RP, Fuster V, Fayad ZA. Molecular, cellular and functional imaging of atherothrombosis. Nat Rev Drug Discov. 2004;3:913-925.
8. Chu B, Phan BA, Balu N, Yuan C, Brown BG, Zhao XQ. Reproduc-ibility of carotid atherosclerotic lesion type characterization using high resolution multicontrast weighted cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2006;8:793-799.
9. Jaffer FA, Libby P, Weissleder R. Molecular imaging of cardiovascular disease. Circulation. 2007;116:1052-1061.
10. Larose E, Kinlay S, Selwyn AP, Yeghiazarians Y, Yucel EK, Kacher DF, Libby P, Ganz P. Improved characterization of atherosclerotic plaques by gadolinium contrast during intravascular magnetic resonance imaging of human arteries. Atherosclerosis. 2008;196:919-925.
11. Sosnovik DE, Nahrendorf M, Weissleder R. Molecular magnetic resonance imaging in cardiovascular medicine. Circulation. 2007;115: 2076-2086. (Pubitemid 46625959)
12. Helft G, Worthley SG, Fuster V, Fayad ZA, Zaman AG, Corti R, Fallon JT, Badimon JJ. Progression and regression of atherosclerotic lesions: monitoring with serial noninvasive magnetic resonance imaging. Circulation. 2002;105:993-998.
13. Sirol M, Aguinaldo JG, Graham PB, Weisskoff R, Lauffer R, Mizsei G, Chereshnev I, Fallon JT, Reis E, Fuster V, Toussaint JF, Fayad ZA. Fibrin-targeted contrast agent for improvement of in vivo acute thrombus detection with magnetic resonance imaging. Atherosclerosis. 2005;182: 79-85. (Pubitemid 41188372)
14. Sirol M, Fuster V, Badimon JJ, Fallon JT, Moreno PR, Toussaint JF, Fayad ZA. Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. Circulation. 2005;112: 1594-1600 (Pubitemid 41324521)
15. von zur Muhlen C, von Elverfeldt D, Moeller JA, Choudhury RP, Paul D, Hagemeyer CE, Olschewski M, Becker A, Neudorfer I, Bassler N, Schwarz M, Bode C, Peter K. Magnetic resonance imaging contrast agent targeted toward activated platelets allows in vivo detection of thrombosis and monitoring of thrombolysis. Circulation. 2008;118: 258-267.
16. Zhao C, Shuke N, Okizaki A, Yamamoto W, Sato J, Iwata K, Kanno T, Hasebe N, Kikuchi K, Aburano T. Naturally formed coronary arterial thrombus detected by In-111 oxine platelet imaging. Clin Nucl Med. 2005;30:492-495.
17. Bates SM, Lister-James J, Julian JA, Taillefer R, Moyer BR, Ginsberg JS. Imaging characteristics of a novel technetium Tc 99m-labeled platelet glycoprotein IIb/IIIa receptor antagonist in patients with acute deep vein thrombosis or a history of deep vein thrombosis. Arch Intern Med. 2003;163:452-456.
18. Dunzinger A, Hafner F, Schaffler G, Piswanger-Soelkner JC, Brodmann M, Lipp RW. 99mTc-apcitide scintigraphy in patients with clinically suspected deep venous thrombosis and pulmonary embolism. Eur J Nucl Med Mol Imaging. 2008;35:2082-2087.
19. Taillefer R. Radiolabeled peptides in the detection of deep venous thrombosis. Semin Nucl Med. 2001;31:102-123.
20. Wang X, Xu L. An optimized murine model of ferric chloride-induced arterial thrombosis for thrombosis research. Thromb Res. 2005;115: 95-100.
21. Gross S, Tilly P, Hentsch D, Vonesch JL, Fabre JE. Vascular wall-produced prostaglandin E2 exacerbates arterial thrombosis and athero-thrombosis through platelet EP3 receptors. J Exp Med. 2007;204: 311-320.
22. Montet X, Montet-Abou K, Reynolds F, Weissleder R, Josephson L. Nanoparticle imaging of integrins on tumor cells. Neoplasia. 2006;8: 214-222.
23. Yamada T, Kidera A. Tailoring echistatin to possess higher affinity for integrin alpha(IIb)beta(3). FEBS Lett. 1996;387:11-15.
24. Xia Z, Wong T, Liu Q, Kasirer-Friede A, Brown E, Frojmovic MM. Optimally functional fluorescein isothiocyanate-labelled fibrinogen for quantitative studies of binding to activated platelets and platelet aggregation. Br J Haematol. 1996;93:204-214.
25. Schwarz M, Meade G, Stoll P, Ylanne J, Bassler N, Chen YC, Hagemeyer CE, Ahrens I, Moran N, Kenny D, Fitzgerald D, Bode C, Peter K. Conformation-specific blockade of the integrin GPIIb/IIIa: a novel anti-platelet strategy that selectively targets activated platelets. Circ Res. 2006;99:25-33.
26. Plow EF, Pierschbacher MD, Ruoslahti E, Marguerie GA, Ginsberg MH. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc Natl Acad Sci USA. 1985; 82:8057-8061.
27. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992;69:11-25.
28. Pierschbacher MD, Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature. 1984;309:30-33.
29. Plow EF, Pierschbacher MD, Ruoslahti E, Marguerie G, Ginsberg MH. Arginyl-glycyl-aspartic acid sequences and fibrinogen binding to platelets. Blood. 1987;70:110-115.
30. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science. 1987;238:491-497.
31. Johansson LO, Bjørnerud A, Ahlström HK, Ladd DL, Fujii DK. A targeted contrast agent for magnetic resonance imaging of thrombus: implications of spatial resolution. J Magn Reson Imaging. 2001;13: 615-618.
32. Lawler J, Hynes RO. An integrin receptor on normal and thrombasthenic platelets that binds thrombospondin. Blood. 1989;74:2022-2027.
33. Scarborough RM, Naughton MA, Teng W, Rose JW, Phillips DR, Nannizzi L, Arfsten A, Campbell AM, Charo IF. Design of potent and specific integrin antagonists: peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem. 1993;268:1066-1073.
34. Goto S, Tamura N, Ishida H. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. J Am Coll Cardiol. 2004;44:316-323.
35. Raju NC, Eikelboom JW, Hirsh J. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nat Clin Pract Car-diovasc Med. 2008;5:766-780.
36. Botnar RM, Buecker A, Wiethoff AJ, Parsons EC, Katoh M, Katsimaglis G, Weisskoff RM, Lauffer RB, Graham PB, Gunther RW, Manning WJ, Spuentrup E. In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent. Circulation. 2004;110:1463-1466.
37. Spuentrup E, Katoh M, Buecker A, Fausten B, Wiethoff AJ, Wildberger JE, Haage P, Parsons EC, Botnar RM, Graham PB, Vettelschoss M, Günther RW. Molecular MR imaging of human thrombi in a swine model of pulmonary embolism using a fibrin-specific contrast agent. Invest Radiol. 2007;42:586-595. (Pubitemid 47051836)
38. Spuentrup E, Katoh M, Wiethoff AJ, Buecker A, Botnar RM, Parsons EC, Guenther RW. Molecular coronary MR imaging of human thrombi using EP-2104R, a fibrin-targeted contrast agent: experimental study in a swine model. Rofo. 2007;179:1166-1173. (Pubitemid 350155124)
39. Rittersma SZ, van der Wal AC, Koch KT, Piek JJ, Henriques JP, Mulder KJ, Ploegmakers JP, Meesterman M, de Winter RJ. Plaque instability frequently occurs days or weeks before occlusive coronary thrombosis: a pathological thrombectomy study in primary percutaneous coronary intervention. Circulation. 2005;111:1160-1165.
40. Knight LC, Primeau JL, Siegel BA, Welch MJ. Comparison of In-111-labeled platelets and iodinated fibrinogen for the detection of deep vein thrombosis. J Nucl Med. 1978;19:891-894.